PDCD1 and melanoma: Analysis of the GSE91061 cohort, consisting of 109 patients with melanoma receiving anti-PD-1, revealed higher AERS scores in the resistant group (Figure 8C, p < 0.01), and the ICI response rate was significantly lower in the AERShigh group compared to the AERSlow group (Figure 8D).